ResMed to Acquire Propeller Health, Leader in Connected Health Solutions for COPD and Asthma, for $ 225 Million
Tuesday, December 04, 2018
ResMed, leader in cloud-based medical devices, and commercial software as a service (SaaS) solutions outside hospitals , announced today that it has reached a definitive agreement for the acquisition of Propeller Health, a digital therapeutics company providing connected healthcare solutions for people with chronic obstructive pulmonary disease (COPD) and asthma.
Designated by Fast Company as "The Most Innovative Company of the Year 2017", Propeller helps patients and their physicians better manage COPD and asthma. Propeller's digital medicine platform is made up of small sensors that easily attach to consumer inhalers, and combine with a mobile app to automatically track medication use, while providing personal feedback and information. Propeller's clinically validated solutions revealed a 58% improvement in treatment adherence, a 48% increase in the number of symptom-free days, and a 53% reduction in the number of emergency room admissions.
Propeller's ability to support people with COPD at Severity Levels II and III complements ResMed's own line of cloud-connected ventilators for people with Stage III and IV COPD, including Astral , Stellar and AirCurve 10 ST-A with iVAPS, as well as ResMed's new Mobi Portable Oxygen Concentrator.
"The acquisition of Propeller is a significant step forward for ResMed, whose ambition is to become the global leader in digital health for COPD," said Mick Farrell, CEO of ResMed. "By working with Propeller's fabulous partners to deliver digital solutions for respiratory care pharmaceuticals, as well as building on our proven ability to support large-scale digital solutions, we are able to improve the daily lives of the more than 380 million people around the world suffering from this crippling chronic disease. "
"Helping users of inhalers increase compliance and avoid hospitalization is part of ResMed's mission to improve the quality of life of people, reduce the impact chronic diseases while reducing health care costs in out-of-hospital care, "said Richie McHale, President of Respiratory Care at ResMed.
"ResMed shares our belief that connected health solutions create significantly better experiences and outcomes for people with chronic respiratory disease," said David Van Sickle, co-founder and CEO of Propeller. "Joining forces allows us to accelerate the adoption of Propeller solutions on a global scale, and to serve as a successful platform for a broad set of pharmaceutical and healthcare partners. "
Propeller is a privately held company based in Madison, Wisconsin with offices in San Francisco. The company will continue to operate autonomously within ResMed's Respiratory Care portfolio. No immediate changes will be made to management, sites or business processes. Mr. Van Sickle will continue in his current position, and will report to Mr. McHale.
Terms of the transaction
Under the terms of the agreement, ResMed will acquire Propeller for $ 225 million, which ResMed will finance primarily through its credit facility. At closing, the transaction is expected to have a dilutive impact on ResMed's non-GAAP quarterly earnings per share, ranging from $ 0.01 to $ 0.02 in fiscal year 2019.
ResMed and Propeller intend to complete the transaction by the end of the third quarter of ResMed's 2019 fiscal year (prior to March 30, 2019), subject to customary closing conditions, including regulatory approvals.
DLA Piper acts as ResMed's legal advisor. Allen & Company LLC acts as exclusive financial advisor to Propeller, and Fenwick & West LLP acts as legal counsel.
About ResMed
ResMed is one of the world's leading connected healthcare companies with more than 6 million cloud-connected devices for day-to-day and remote patient monitoring. and change life with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. His 6,000-strong team works to improve the quality of life for patients, reduce the impact of chronic disease, and reduce health care costs in more than 120 countries. ResMed.com
About Propeller Health
Propeller Health, a leading provider of digital therapeutics solutions, is committed to the development and commercialization of improved medicines in measurable ways. Propeller creates products to more effectively treat respiratory disease, and improve patient outcomes through connectivity, analytics, and accompanying digital experiences. The Propeller platform is used by many patients, physicians and health organizations, based in the United States, Europe and Asia. For more information, visit www.propellerhealth.com .
Forward-looking statements
Other risks and uncertainties are described in ResMed's periodic reports filed with the Securities and Exchange Commission of the United States. ResMed does not undertake to update its forward-looking statements.
The text of the communiqué resulting from a translation must in no way be considered official. The only version of the release that is authentic is that of the release in its original language. The translation will always have to be confronted with the source text, which will make jurisprudence.
contacts
ResMed Contacts
For Media:
Jayme Rubenstein
+1 858.836.6798
news@resmed.com
For Investors:
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com
Contact Propeller Health
Mike Pilarz
+1 608.709.8729
press @ propellerhealth.com